-
6
-
-
0031277578
-
Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and src family tyrosine kinases
-
(1997)
Pharmacol Ther
, vol.76
, pp. 55-71
-
-
Showalter, H.D.1
Kraker, A.J.2
-
8
-
-
0031957879
-
Current progress towards the development of tyrosine kinase inhibitors as anticancer agents
-
(1998)
Emerging Drugs
, vol.3
, pp. 279-292
-
-
Bridges, A.J.1
-
9
-
-
0032830412
-
The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases
-
(1999)
Curr Med Chem
, vol.6
, pp. 825-843
-
-
Bridges, A.J.1
-
10
-
-
0030774045
-
Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
-
(1997)
Cancer Res
, vol.57
, pp. 4838-4848
-
-
Moyer, J.D.1
Barbacci, E.G.2
Iwata, K.K.3
Arnold, L.4
Boman, B.5
Cunningham, A.6
DiOrio, C.7
Doty, J.8
Morin, M.J.9
Moyer, M.P.10
Neveu, M.11
Pollack, V.A.12
Pustilnik, L.R.13
Reynolds, M.M.14
Sloan, D.15
Theleman, A.16
Miller, P.17
-
12
-
-
15444361739
-
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methyl- amino-substituted derivatives of 4-[(3-bromophenyl)amino]-6(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factor
-
(1998)
J Med Chem
, vol.41
, pp. 742-751
-
-
Rewcastle, G.W.1
Murray, D.K.2
Elliott, W.L.3
Fry, D.W.4
Howard, C.T.5
Nelson, J.M.6
Roberts, B.J.7
Vincent, P.W.8
Showalter, H.D.9
Winters, R.T.10
Denny, W.A.11
-
13
-
-
0029975029
-
Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)-amino]pyrido[d]pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor
-
(1996)
J Med Chem
, vol.39
, pp. 1823-1835
-
-
Rewcastle, G.F.1
Palmer, B.D.2
Thompson, A.M.3
Bridges, A.J.4
Cody, D.R.5
Zhou, H.M.6
Fry, D.W.7
McMichael, A.8
Denny, W.A.9
-
15
-
-
9844235351
-
Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines
-
(1997)
J Med Chem
, vol.40
, pp. 3601-3616
-
-
Traxler, P.1
Bold, G.2
Frei, J.3
Lang, M.4
Lydon, N.5
Mett, H.6
Buchdunger, E.7
Meyer, T.8
Mueller, M.9
Furet, P.10
-
18
-
-
0030057160
-
Phenylaminopyrimidine (PAP) derivatives: A new class of potent and selective inhibitors of protein kinase C (PKC)
-
(1996)
Arch Pharm (Weinheim, Ger.)
, vol.329
, pp. 371-376
-
-
Zimmermann, J.1
Caravatti, G.2
Mett, H.3
Meyer, T.4
Mueller, M.5
Lydon, N.B.6
Fabbro, D.7
-
19
-
-
0030665627
-
1-Oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase
-
(1997)
Bioorg Med Chem Lett
, vol.7
, pp. 2903-2908
-
-
Barvian, M.R.1
Panek, R.L.2
Lu, G.H.3
Kraker, A.J.4
Amar, A.5
Hartl, B.G.6
Hamby, J.M.7
Showalter, H.D.H.8
-
20
-
-
0032893263
-
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
-
(1999)
Cancer Res
, vol.59
, pp. 99-106
-
-
Fong, T.A.T.1
Shawver, L.K.2
Sun, L.3
Tang, C.4
App, H.5
Powell, T.J.6
Kim, Y.H.7
Schreck, R.8
Wang, X.9
Risau, W.10
Ullrich, A.11
Hirth, K.P.12
McMahon, G.13
-
24
-
-
0032695910
-
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
-
(1999)
Pharmacol Exp Ther
, vol.291
, pp. 739-748
-
-
Pollack, V.A.1
Savage, B.D.M.2
Baker, D.A.3
Tsaparikos, K.E.4
Sloan, D.E.5
Moyer, J.D.6
Barbacci, E.G.7
Pustilnik, L.R.8
Smolarek, T.A.9
Davis, J.A.10
Vaidya, M.P.11
Arnold, L.D.12
Doty, J.L.13
Iwata, K.K.14
Morin, M.J.15
-
25
-
-
0034611617
-
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
-
(2000)
J Med Chem
, vol.43
, pp. 1380-1397
-
-
Smaill, J.B.1
Rewcastle, G.W.2
Loo, J.A.3
Greis, K.D.4
Chan, O.H.5
Reyner, E.L.6
Lipka, E.7
Showalter, H.D.8
Vincent, P.W.9
Elliott, W.L.10
Denny, W.A.11
-
27
-
-
0003253888
-
EKB-569; a new irreversible inhibitor of epidermal growth factor receptor tyrosine kinase for the treatment of cancer
-
Poster 388
-
11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, 7-10 November, 2000
-
-
Greenberger, L.M.1
Discafani, C.2
Wang, Y.F.3
Tsou, H.R.4
Overbeck, E.G.5
Nilakantan, R.6
-
28
-
-
0003249280
-
Pyrrolo[2,3-d]pyrimidine and Pyrazolo[3,4-d]pyrimidine derivatives as selective inhibitors of the EGFR tyrosine kinase
-
in press
-
(2001)
New Prospects in Anticancer Agents for the 21st Century. ACS book
-
-
Caravatti, G.1
Brüggen, J.2
Buchdunger, E.3
Cozens, R.4
Furet, P.5
Lydon, N.6
O'Reilly, T.7
Traxler, P.8
-
31
-
-
0034212763
-
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
-
(2000)
Cancer Res
, vol.60
, pp. 2926-2935
-
-
Bruns, C.J.1
Solorzano, C.C.2
Harbison, M.T.3
Ozawa, S.4
Tsab, R.5
Fan, D.6
Abbruzzese, J.7
Traxler, P.8
Buchdunger, E.9
Radinsky, R.10
Fidler, I.J.11
-
34
-
-
0030561092
-
The role of vascular endothelial growth factor in blood vessel formation
-
(1996)
TIBC
, vol.6
, pp. 454-456
-
-
Breier, G.1
Risau, W.2
-
35
-
-
0003269592
-
Prospects for anti-angiogenic therapies based upon VEGF inhibition. New prospects in anticancer agents for the 21st century
-
in press
-
(2001)
ACS book
-
-
Furet, P.1
Manley, P.W.2
-
36
-
-
0033947625
-
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinasesuseful as antagonists of tumor-driven angiogenesis
-
(2000)
J Med Chem
, vol.43
, pp. 2310-2323
-
-
Bold, G.1
Altmann, K.H.2
Frei, J.3
Lang, M.4
Manley, P.W.5
Traxler, P.6
Wietfeld, B.7
Buchdunger, E.8
Cozens, R.9
Ferrari, S.10
Furet, P.11
Hofmann, F.12
Martiny-Baron, G.13
Mestan, J.14
Rösel, J.15
Sills, M.16
Stover, D.17
Acemoglu, F.18
Boss, E.19
Emmenegger, R.20
Lässer, L.21
Masso, E.22
Roth, R.23
Schlachter, C.24
Vetterli, W.25
Wyss, D.26
Wood, J.M.27
more..
-
37
-
-
0034655182
-
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
-
(2000)
Cancer Res
, vol.60
, pp. 2178-2189
-
-
Wood, J.M.1
Bold, G.2
Buchdunger, E.3
Cozens, R.4
Ferrari, S.5
Frei, J.6
Hofmann, F.7
Mestan, J.8
Mett, H.9
O'Reilly, T.10
Persohn, E.11
Rösel, J.12
Schnell, C.C.13
Stover, D.14
Theuer, A.15
Towbin, H.16
Wenger, F.W.17
Woods-Cook, K.18
Menrad, A.19
Siemeister, G.20
Schimer, M.21
Thierauch, K.H.22
Schneider, M.R.23
Drevs, J.24
Martiny-Baron, G.25
Totzke, F.26
Marmé, D.27
more..
-
38
-
-
0034016273
-
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation
-
(2000)
Clin Cancer Res
, vol.6
, pp. 957-965
-
-
Yano, S.1
Herbst, R.S.2
Shinohara, H.3
Knighton, B.4
Bucana, C.D.5
Killion, J.J.6
Wood, J.7
Fidler, J.J.8
-
43
-
-
0029947186
-
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
-
(1996)
Nat Med
, vol.2
, pp. 561-566
-
-
Druker, B.J.1
Tamura, S.2
Buchdunger, E.3
Ohno, S.4
Segal, G.M.5
Fanning, S.6
Zimmermann, J.7
Lydon, N.B.8
-
44
-
-
0030031766
-
Inhibitor of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
-
(1996)
Cancer Res
, vol.56
, Issue.1
, pp. 100-104
-
-
Buchdunger, E.1
Zimmermann, J.2
Mett, H.3
Meyer, T.4
Mueller, M.5
Druker, B.J.6
Lydon, N.B.7
-
46
-
-
0031454003
-
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
-
(1997)
Blood
, vol.90
, pp. 4947-4952
-
-
Carroll, M.1
Ohno-Jones, S.2
Tamura, S.3
Buchdunger, E.4
Zimmermann, L.5
Lydon, N.B.6
Gilliland, D.G.7
Druker, B.J.8
-
47
-
-
15444350807
-
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
-
(1998)
Clin Cancer Res
, vol.4
, pp. 1661-1672
-
-
Beran, M.1
Cao, X.2
Estrov, Z.3
Jeha, S.4
Jin, G.5
O'Brien, S.6
Talpaz, M.7
Arlinghaus, R.B.8
Lydon, N.B.9
Kantarjian, H.10
-
49
-
-
0031409736
-
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis
-
(1997)
Blood Cell Mole Dis
, vol.23
, pp. 380-394
-
-
Gambacorti-Passerini, C.1
Le Coutre, P.2
Mologni, L.3
Fanelli, M.4
Bertazzoli, C.5
Marchesi, E.6
Di Nicola, M.7
Biondi, A.8
Corneo, G.M.9
Belotti, D.10
Pogliani, E.11
Lydon, N.B.12
-
52
-
-
0033585504
-
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
-
(1990)
J Natl Cancer Inst
, vol.91
, pp. 163-168
-
-
Le Coutre, P.1
Mologni, L.2
Cleris, L.3
Marchesi, E.4
Buchdunger, E.5
Giardini, R.6
Formelli, F.7
Gambacorti-Passerini, C.8
|